We are thrilled to announce the publication of a scientific paper titled:
“From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy” authored by
E. Pinto, L. Lione, M. Compagnone, M. Paccagnella, E. Salvatori, M. Greco, V. Frezza, E. Marra, L. Aurisicchio, G. Roscilli & A. Conforti.
Our research highlights how CAR-T cell therapy has revolutionized cancer treatment and how is hindered by a complex, time-consuming, and expensive ex vivo manufacturing process.
Our review explores an innovative alternative: the in vivo CAR-T cell production, where T cells are reprogrammed directly in the body using injectable viral or nanocarrier platforms.
This simplifies the process, reduces costs, and may lower toxicities like cytokine release syndrome, paving the way for broader patient access.
We are excited about the potential of this innovative approach for a more accessible and effective CAR-T cell therapy for patients worldwide!
Read the full paper to learn more about the challenges, advances, and future of in vivo CAR-T therapy.
